AUCTORES
Globalize your Research
Research Article
*Corresponding Author: Sara Parsons, Respiratory Physiology, St George’s University Hospitals NHS Foundation Trust, Blackshaw Road, Tooting, London, SW17 0QT, and Sonia A.L. Corrêa, Faculty of Science and Engineering, Department of Life Sciences John Dalton Building, Manchester
Citation: Sara Parsons and Sonia A.L. Corrêa, (2024), Positive airway pressure improves amnestic mild cognitive impairment in patients diagnosed with obstructive sleep apnoea hypopnoea syndrome. A review of the evidence, International Journal of Clinical Case Reports and Reviews, 17(2); DOI:10.31579/2690-4861/428
Copyright: © 2024, Sara Parsons and Sonia A.L. Corrêa. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 22 March 2024 | Accepted: 10 April 2024 | Published: 18 April 2024
Keywords: obstructive sleep apnoea; glymphatic system; Alzheimer’s disease; positive airway pressure; cognition
There is growing clinical evidence showing the impact of sleep disturbance on the development of Alzheimer’s disease (AD). It has been proposed that intermittent hypoxia and sleep fragmentation, which are hallmarks of obstructive sleep apnoea hypopnoea syndrome (OSAHS), are physiological changes that may contribute to cognitive impairment. Sleep fragmentation reduces slow-wave sleep duration affecting the efficiency of the brain clearance system, allowing metabolic proteins to accumulate. These proteins contribute to neurodegeneration, brain atrophy, and cognitive impairment. Improvements in fluid diffusion which leads to the reduction in the accumulation of metabolic proteins, have been observed after positive airway pressure (PAP) treatment. Treating OSAHS may be effective in reducing the risk of neuronal damage and improve cognitive function.
This review outlines the current knowledge associating OSAHS and AD and discusses the effect of PAP treatment on cognitive function, AD biomarkers, and the brain clearance system.
Aβ – amyloid beta
AD – Alzheimer’s disease
AHI – apnoea/hypopnoea index
aMCI – amnestic mild cognitive impairment
CSF – cerebrospinal fluid
MCI – mild cognitive impairment
MRI – magnetic resonance imaging
OSAHS – obstructive sleep apnoea hypopnoea syndrome
PAP – positive airway pressure
Obstructive sleep apnoea hypopnoea syndrome (OSAHS) is characterised by recurrent episodes of partial or complete pharyngeal collapse, causing a reduction or cessation of airflow [1]. This leads to key physiological changes during sleep including intermittent hypoxia, swings in intrathoracic pressure and sleep fragmentation, leading to alterations in the sleep architecture [2-5].
Alzheimer’s disease (AD) is regarded as a world-wide epidemic that currently cannot be prevented, treated, nor slowed down [5,6]. Memory loss is the main feature of amnestic mild cognitive impairment (aMCI) which is the prodromal phase to AD [7]. It is imperative for early identification of those with an increased probability of developing aMCI to allow for early treatment of the AD risk factors [4,8].
There is discrepancy in the information associating the prevalence of OSAHS in the AD population. A potential reason for the differing results is largely dependent on the populations studied (community compared to nursing home) which may result in survivor bias [4].
In addition, the sleep and breathing measurements analysed vary and so the diagnosis of OSAHS may be under or over-estimated when gold-standard measures are not used (respiratory parameters e.g. oxygen desaturation index compared to apnoea hypopnoea index (AHI)) [4]. For example, a systematic review of 5 studies undertaken by Mubashir et al. [9] found OSAHS prevalence ranging between 11 and 71% in the mild cognitively impaired (MCI) population. The large prevalence range highlights the methodological differences across the 5 studies, with 1 study using qualitative methods and another relying on the self-reporting from participants to diagnose OSAHS. Interestingly, two of the studies using objective methods to diagnose OSAHS demonstrated an OSAHS prevalence of 70 and 71% in the MCI population. In contrast, the study relying of the self-reporting of OSAHS demonstrated a significantly lower prevalence at 11%. This suggests the OSAHS is highly prevalent in the MCI population.
The mechanisms mediating the pathological alterations in cognition observed in OSAHS patients are unclear. There are hypotheses suggesting that intermittent hypoxia and sleep fragmentation, key features of OSAHS, cause cognitive decline contributing to the development of aMCI and eventually AD [1-5]. Fundamentally, intermittent hypoxia and sleep fragmentation cause changes in the sleep architecture, oxidative stress, and intrathoracic pressure swings (Figure 1).
Figure 1: Proposed pathways linking OSAHS to cognitive impairment. Two key physiological features of OSAHS, sleep fragmentation and intermittent hypoxia, are proposed to cause cognitive dysfunction [30,49]. These features are proposed to promote oxidative stress, reduce slow wave sleep (SWS) duration, generate intrathoracic pressure swings, and reduce rapid eye movement sleep (REM) [11,18,49,60]. The proposed pathways by which each of these physiological changes leads to cognitive impairment will be discussed in Figure. 1a and 1b respectively.
A reduction in slow wave sleep (SWS) and changes in the intrathoracic pressure causes a reduction in the fluid diffusivity through the brain, which leads to impairments in the clearance pathway, known as the glymphatic system (Figure 1a). When the glymphatic clearance is reduced it promotes the accumulation of metabolic waste products in the brain.
This can cause over excitability in the brain immune cells, such as microglia, causing inflammation, cell death, and neurodegeneration. Over time this can eventually cause neuronal death, changes in brain structure and function leading to cognitive decline (Figure 1a) [10-12]. This will be discussed further in the next section.
Figure 1a. Reduction in slow wave and rapid eye movement sleep, and intrathoracic pressure swings, has been proposed to reduce the activity of the glymphatic system by reducing the fluid diffusivity across the brain [11,18,36,37,38,60]. Reduction in brain clearance promote an increase in accumulated metabolites in the brain (such as amyloid beta and tau proteins) [6,56]. An increase in these proteins in the brain have been proposed to form a bidirectional relationship with sleep and therefore contributing to further slow wave sleep disruption due to inflammation interfering with sleep generating pathways [5,64]. This causes a repetitive cycle of events and hence further reductions in the glymphatic system activity [64]. Protein accumulation activates astrocytes and microglia as they clear these metabolites from the interstitial space. These cells became overactivated as the load of metabolites increase which leads to inflammation. Inflammatory processes are harmful to neurones affecting synaptic plasticity. In the long-term this inflammatory process leads to neuronal death causing structural changes in the brain [37,58]. Deficits in synaptic plasticity and neuronal death leads to cognitive impairment [11,29,31,35].
Positive airway pressure (PAP), the gold standard treatment for OSAHS [13], stents the upper airway allowing for unrestricted airflow [14]. This treatment method maintains oxygen levels during sleep and improves quality of sleep. There is substantial evidence showing the efficacy of this treatment to recover the physiological changes including hypoxaemia and sleep fragmentation in OSAHS patients [15-17]. Due to the relationship between OSAHS and AD, PAP treatment has been proposed to improve cognitive impairment through the promotion of sleep consolidation and maintaining stable nocturnal oxygen levels [18]. Although the mechanism by which PAP treatment improves cognition in OSAHS patients [17,19] is not yet known, there are experimental findings supporting a delayed onset of MCI after PAP treatment [8,17,19,20,21]. This observation is not limited to aMCI and hence Alzheimer’s disease and may include cognitive impairment associated with other diseases such as Parkinson’s
disease [7,17]. Nonetheless, OSAHS has been often regarded as a potential risk factor for developing AD [17,22,23].
The aim of this review is to present current evidence to establish whether the efficacy of PAP treatment ameliorates cognitive impairment in patients with OSAHS. We will also establish whether fluid diffusivity efficiency in the brain is improved with PAP treatment, and whether PAP treatment impacts cognitive function and levels of AD biomarkers in the cerebrospinal fluid (CSF) and blood.
2. Method
A literature search was performed using three databases from January 2003 until March 2024 and using the search term combinations in Table 1. References obtained were also hand searched for further articles that may have been missed.
| Database | Search term |
| PubMed | (“Mild cognitive impairment” OR “cognitive decline” OR “cognitive dysfunction” OR “mild cognitive deficit” OR “Alzheimer disease” OR AD OR amyloid OR “MCI” OR “amnestic mild cognitive impairment” OR “degenerative disease” OR “amyloid precursor protein” OR pre Alzheimer OR pre-Alzheimer OR “prodromal Alzheimer” OR “preclinical Alzheimer” OR “pre-clinical Alzheimer” OR “mild neurocognitive disorder” OR Alzheimer [Title/Abstract]) AND (OSA OR “obstructive sleep apnoea” OR “sleep disordered breathing” OR “sleep disorder” [Title/Abstract]) AND (CPAP OR “continuous positive airway pressure” OR “positive pressure” OR MRI OR “magnetic resonance imaging” [Title/Abstract]) |
| CINAHL | (“Mild cognitive impairment” OR “cognitive decline” OR “cognitive dysfunction” OR “mild cognitive deficit” OR “Alzheimer disease” OR AD OR amyloid OR “MCI” OR “amnestic mild cognitive impairment” OR “degenerative disease” OR “amyloid precursor protein” OR preAlzheimer OR pre-Alzheimer OR “prodromal Alzheimer” OR “preclinical Alzheimer” OR “pre-clinical Alzheimer” OR “mild neurocognitive disorder” OR Alzheimer [Abstract]) AND (OSA OR “obstructive sleep apnoea” OR “sleep disordered breathing” OR “sleep disorder” [Abstract]) AND (CPAP OR “continuous positive airway pressure” OR “positive pressure” OR MRI OR “magnetic resonance imaging” [Abstract]) |
| Web of Science | (“Mild cognitive impairment” OR “cognitive decline” OR “cognitive dysfunction” OR “mild cognitive deficit” OR “Alzheimer disease” OR AD OR amyloid OR “MCI” OR “amnestic mild cognitive impairment” OR “degenerative disease” OR “amyloid precursor protein” OR preAlzheimer OR pre-Alzheimer OR “prodromal Alzheimer” OR “preclinical Alzheimer” OR “pre-clinical Alzheimer” OR “mild neurocognitive disorder” OR Alzheimer [Abstract]) AND (OSA OR “obstructive sleep apnoea” OR “sleep disordered breathing” OR “sleep disorder” [Abstract]) AND (CPAP OR “continuous positive airway pressure” OR “positive pressure” OR MRI OR “magnetic resonance imaging” [Abstract]) |
AD, Alzheimer’s disease; MCI, mild cognitive impairment; OSA, obstructive sleep apnoea; CPAP, continuous positive airway pressure; MRI, magnetic resonance imaging.
Table 1: Search terms used for specific databases.
A total of 45 studies were found. Of the 45, 15 studies discussed the hypothesised glymphatic system in relation to sleep [11,12,23-35], 5 studies assessed the impact of PAP on brain fluid diffusivity in patients with OSAHS [36-40], 4 studies assessed the influence of PAP treatment on the level of AD biomarkers [29,31,41,42], 11 studies measured the impact of PAP treatment on cognitive function in OSAHS [1,4,14,43-50] and 10 studies measured the impact of PAP treatment on cognitive function in OSAHS and aMCI/AD [7, 8,17,20,21,51-55].
To address the aim of this review, the impact of PAP treatment on sleep fragmentation and intermittent hypoxia will be discussed on 1) the functioning of the glymphatic system; 2) the brain fluid diffusivity and volume changes in white and grey matter structures via magnetic resonance imaging (MRI); 3) levels of biomarkers for AD in the CSF and blood and 4) cognitive function in OSAHS patients with and without aMCI.
4.1. Sleep fragmentation, intermittent hypoxia, and the glymphatic system.
The importance of sleep for optimal function of the glymphatic system has been previously reported in humans [23,28-32,34].
It has been hypothesised that the glymphatic system is most effective during slow wave sleep; with the purpose of CSF influx into the brain, mixing with the interstitial fluid containing the metabolic waste such as amyloid beta (Aβ), which accumulates during wakefulness. The combined fluid containing the proteins are washed out of the parenchyma into the CSF and the blood stream via the blood brain barrier, for elimination through the kidneys and liver [23,28,30,31,34,56].
Therefore, if the glymphatic system is most effective during sleep then fragmented sleep, a sleep pattern observed in those with OSAHS, causes deficiencies in the glymphatic clearance. This supports the amyloid cascade theory, a persuasive model for the development of AD [6]. This relates to the discrepancy in the production and clearance of Aβ, which is secreted mainly by neurons, and subsequently the effectiveness of the glymphatic system [6,56]. If this pattern of sleep fragmentation persists and glymphatic clearance is impaired, there will be an increase in the accumulation and aggregation of insoluble Aβ peptides which form extracellular plaques [29,30,34].
The mechanism of increased extracellular tau proteins in the brain is less characterised [56]. It has been suggested that tau is a product of axonal loss mainly due to increase in hyperphosphorylated tau which cannot bind to the microtubules of the axon. Therefore, support from tau is no longer available causing axon instability and neuronal death leading to neurodegeneration (Figure 1a) [11,29,31,35,57,58]. This is likely to be caused by intermittent hypoxia leading to inflammation in the brain (Figure 1a).
To add insult to injury, intermittent hypoxia, another feature of OSAHS, also contributes to neurodegeneration by several physiological mechanisms including inflammation, due to an increase in oxidative stress [49]. An increase of free radical formation and hence an imbalance between antioxidants is a consequence of oxidative stress, which increase release of inflammatory factors and endothelial cell damage (Figure 1b) [12,24,25,26,27,33]. Oxidative stress can cause an increase in the microglia (immune cells of the central nervous system) and astrocyte (subtype of glial cells) activity [49,59]. There is essentially a role reversal of these cells. For example, instead of the protective function that microglia provide by clearing Aβ proteins, when the cells are overactivated they can produce harmful amount of neurotoxic pro-inflammatory factors such as tumour necrosis factor alpha, interleukin [48,49,59]. These substances have been shown to be harmful to neurons, can cause an increase in inflammation and may influence tau pathology [49,59].
Figure 1b. Proposed physiological changes in OSAHS leading to increase in oxidative stress and cognitive impairment [49]. Oxidative stress has been proposed to cause an increase in the microglial and astrocyte activity, which in response release pro-inflammatory factors causing inflammation in the brain [48,59]. Increase in the inflammatory factors further promotes immune cell and release of inflammatory factors [59]. In addition, inflammation, oxidative stress, and blood flow surges can cause endothelial damage and changes in the blood-brain barrier integrity [56,57]. This reduces permeability of the blood brain barrier, allowing easy access of foreign agents into the brain [56]. Both the inflammation and the endothelial damage can lead to neuronal dysfunction and neuronal death and ultimately cognitive impairment [12,26,49,56].
Unstable levels of oxygen in the blood cause a rise and fall in blood pressure, the resultant blood pressure swings may cause hypertension [29]; a known risk factor for AD and comorbidity of OSAHS. Furthermore, the repetitive nature of respiratory events causes surges in
the intracranial and intrathoracic pressure (Figure 1a). These high-pressure swings may impede the glymphatic flow due to increased resistance and hence impede drainage efficiency from the glymphatic system [28,60].
This demonstrates the complex and intricate relationship that can result in the accumulation of Aβ and cellular death, which are key features of AD, through the two overarching mechanisms of intermittent hypoxia and
sleep fragmentation; both of which are commonly experienced in OSAHS.
4.2. Effect of positive airway pressure treatment on the glymphatic system.
As previously discussed, intermittent hypoxia has been hypothesised to contribute to neuroinflammation ultimately leading to widespread neuronal damage and brain atrophy (Figure 1,1a,1b). It has been observed that OSAHS patients demonstrate a reduction in the diffusivity volume in the brain [37,39,61-63] suggesting alterations in the brain structure of the grey and white matter. Structural changes due to cellular membrane destruction can occur, in addition, inflammation can cause an increase in water diffusivity and blood vessel damage [37]. All of which may hinder fluid flow across the brain and therefore reducing glymphatic clearance [62]. This suggests the presence of intracellular cytotoxic oedema and increased production of microglial and astrocyte activity [62], as previous discussed in section 4.1. This will further contribute to the accumulation of Aβ.
The effects of PAP treatment on brain fluid diffusivity have been observed using MRI. Albeit there are very few studies that have assessed the full impact of PAP as an intervention on the glymphatic function in OSAHS patients. Nonetheless, five longitudinal studies using MRI measures were identified.
In a group of 17 severe OSAHS male patients using PAP therapy for 3 months, Canessa et al [36] found the reversal of grey matter volume in the hippocampal and frontal cortex regions of the brain. Supporting these findings, Rosenzweig et al [38] found a reduction in fibres in the left hippocampus, bilateral globus pallidus, and mid-posterior part of the corpus callosum in OSAHS patients. After using PAP for 1 month these observations were no longer found, suggesting adaptation of the neuroplastic structures which also correlated to reduced somnolence and improvements in attention and memory.
The importance of glymphatic drainage was demonstrated by Wang et al [40]. They found enlarged perivascular spaces in the bilateral frontal cortex and basal ganglia in OSAHS patients and even more prominently so in the severely hypoxic OSAHS patients. Both of which improved with PAP treatment [36,37,40]. These findings suggest that PAP may help to restore brain structure and glymphatic function and consequently improve cognitive impairment because of restoring sleep architecture and improving cerebral perfusion [16].
Interestingly, Zhang et al [39] compared sleepy and non-sleepy OSAHS patients treated with PAP for one month, both groups demonstrating an adequate adherence of ≥6 hours per night. They found that the white matter measured by mean diffusivity was higher in the sleepy group when compared to the non-sleepy group. However, optimisation of PAP treatment only relied on PAP reported AHI, other variables influencing PAP effectiveness such as interface leak was not reported. The severity of white matter damage before treatment for each group was not measured, and therefore it is unknown if groups were comparable before starting treatment. Although speculative, the amount of white matter damage may improve after a longer period using PAP treatment.
The arbitrary follow up periods of one and three months are often used. This may stunt potential alterations in the white and grey matter. This was highlighted in a controlled prospective study by Castronovo et al [37]. They found that impaired cognitive function was associated with white matter structural changes measured via fractional ansiotropy and mean diffusivity in the OSAHS group pre-treatment. Reductions in fractional ansiotropy and hence white matter integrity was found in several brain regions including the parietal, frontal, and prefrontal cortical areas. This suggests that OSAHS has a significant impact on white matter in the patient’s brain. However, after 12 months of PAP treatment, repeat measurements of fractional ansiotropy and mean diffusivity demonstrated more notable changes in the reversal in white matter integrity when compared to three month follow up measurements. This suggests the repair of neuronal injury from intermittent hypoxia is a longer process. This was also correlated with improvements in attention, executive function, and memory.
4.3. Effect of positive airway pressure treatment on levels of biomarkers for AD in OSAHS patients.
There is a proposed bidirectional relationship between OSAHS and AD relating to protein accumulation of Aβ and tau and reduced slow wave sleep (Figure 1a) [5]. It has been established with suggested that a lack of slow wave sleep contributes to the formation of Aβ plaques [6, 10, 11], the accumulation of Aβ in turn hinders slow wave sleep, generating a vicious cycle of events [64]. The mechanisms behind this two-way relationship remain unclear however, it has been proposed to be influenced by inflammation [5,6,64] as described in section 4.1. This proposed relationship further supports the amyloid cascade theory (Section 4.1) [6] which leads to neurodegeneration and AD pathology.
According to Mullins et al [16], the number of papers demonstrating the effect of PAP on levels of CSF and blood AD biomarkers is sparse. Nonetheless, PAP has been shown to alter sleep macrostructure in OSAHS patients, particularly slow wave sleep duration and sleep efficiency. Improvements in levels of pathological Aβ and tau biomarkers when OSAHS patients have been using PAP is thought to be due to the restoration of slow wave sleep [5]. Similar findings were found in several papers and are discussed below.
A study by Madaeva et al [31] demonstrated an increase in slow wave sleep positively correlated to plasma Aβ42 levels in a group of moderate and severe OSAHS treated with PAP for three months. Restoring the sleep architecture to a standard pattern by increasing the sleep quality and duration due to PAP treatment may improve glymphatic drainage.
In support of these findings, Liguori et al [29] demonstrated higher levels of Aβ42 in the CSF of those using PAP compared to non-PAP users. This suggests that the PAP group were more likely to experience consolidated sleep and thus less sleep fragmentation which favoured a more efficient clearance of Aβ from the brain. Interestingly, they also supported the influence of intermittent hypoxia on cognition and neurodegeneration by demonstrating that lower levels of Aβ in the CSF correlated with poorer cognitive function and lower oxygen saturations.
A similar study by Liu et al [42] compared plasma biomarkers Aβ42 and T-tau in PAP and non-PAP OSAHS patients. Those using PAP treatment demonstrated a significantly reduced level of both biomarkers compared to the non-PAP group after 3 months of treatment. The individuals assigned to each group was by self-selection, and therefore motivational bias to use PAP therapy may have been present. Those in the PAP group also demonstrated higher baseline in the Epworth sleepiness score compared to the non-PAP group supporting a further motivational influence. Nonetheless, the physiological change in biomarkers supports that PAP treatment may be effective in reducing cognitive dysfunction.
Furthermore, Ju et al [41] findings support the proposed bidirectional relationship and found that PAP treatment significantly increased slow wave sleep duration which correlated with improved pathological levels of Aβ42 in the CSF. Surprisingly, this was the only study found that used auto-titrating PAP to ascertain the 90th percentile pressure over a ≥2-week period. Thus, allowing for the monitoring of night-to-night variation as opposed to a split night or depending on a single night titration study [7,21,51-53]. Titrating over a longer period will argueably improve the efficacy of treatment.
4.4. Positive airway pressure treatment and cognitive function in OSAHS and in OSAHS and aMCI.
In recent years there has been an increased interest in the cognitive effects of PAP treatment in those with OSAHS. However, more research is needed to assess PAP as an intervention in those with OSAHS and cognitive impairment. There have been few longitudinal and randomised controlled trials assessing the effects of PAP treatment on cognition specifically in OSAHS patients with aMCI. Nevertheless, randomised controlled trials have shown cognitive improvements in OSAHS patients with AD when using PAP treatment [20,51-53]. Findings from these studies demonstrated significant improvements in slow wave sleep, mood, cognition, and sleepiness; suggesting that aMCI and AD patients with OSAHS may benefit from PAP treatment.
Studies have hypothesised that intermittent hypoxia and sleep fragmentation is associated with cognitive impairment due to reduced SWS and REM, oxidative stress, and intrathoracic pressure swings (Figure 1), all contributing to neurodegeneration and thus aMCI (Figures 1a and 1b) [1,2,18]. PAP treatment may therefore improve cognitive impairment by consolidating sleep and normalising nocturnal oxygen levels, and consequently restore the sleep architecture and reduce daytime somnolence [3]. In support, Dandan-Zong et al [1] found a reduction in the inflammatory marker’s interleukin 6 and interleukin 8 in PAP users compared to pre-treatment, which also correlated with improved cognitive function assessment scores. Ou et al [49] also demonstrated improvements in inflammatory markers (TAR DNA-binding protein 43, histone deacetylase 6 and peroxiredoxin-1) and cognitive function in patients with severe OSAHS using PAP treatment for 12 weeks. Furthermore, Zong et al [48] has shown that 12 weeks of PAP treatment can reduce levels of inflammation and oxidative stress by preventing the intermittent hypoxia and hence the repetitive deoxygenation and reoxygenation nature of OSAHS [48]. Consequently, the inflammatory proteins involved in neuro-inflammation and oxidative stress pathway are reduced, improving endothelial dysfunction allowing for unrestricted blood flow and hence improves cognitive impairment in OSAHS (Figure 1b) [48].
A study by Ferini-Strambi et al [43] showed an improvement in attention and somnolence levels after 15 days of PAP treatment with titration over one night using polygraphy, in 16 severe OSAHS patients. However, these findings should be interpreted with caution as the study was underpowered due to the small sample size with a predominantly male cohort and only severe OSAHS cases were included in the study. No further enhancements in cognition were found after 4 months of PAP treatment, and the OSAHS group did not achieve full resolution of cognitive deficits. This supports the hypothesis that intermittent hypoxia causes irreversible hypoxic injury to areas of the brain such as the hippocampus and frontal cortex [15,65]. This is likely to exhibit the most extreme influence of intermittent hypoxia and sleep fragmentation [22,32,45]; and hence is likely to generate a more adverse impact including levels of oxidative stress, inflammation, intrathoracic pressure swings, reduction in slow wave sleep. Overall, this causes neuronal death with irreversible damage in the brain structure and function (Figures 1a and 1b). Consequently, the effects of PAP treatment are limited once significant neuronal death has happened. This suggests the timing of PAP treatment is imperative for prevention of irreversible damage and may be more effective as a preventative treatment for neurodegeneration when initiated early in those with OSAHS.
In support, a systematic review by Bubu et al [4] concluded PAP treatment improves attention and vigilance in OSAHS patients, but other cognitive domains such as visuospatial organisational skills and mental set-shifting performance, tend to remain impaired. Similarly, a meta-analysis by Wang et al [66] showed only attention and processing speed improved with PAP. In contrast, two meta-analyses by Olaithe and Bucks [45] and Pollicina et al [47] found an improvement in executive function with PAP treatment. Whereas Lajoie et al [55] found multiple areas of cognition improved with PAP treatment including global cognition, psychomotor speed, and executive function.
In addition, it should not be underestimated the improvement in daytime hypersomnolence when using PAP. Findings from the APPLES study showed subjective and objective improvements in sleepiness in PAP users compared to sham PAP over a 6-month period in OSAHS [44], suggesting a reduction in sleep fragmentation. Although only mild improvements in executive and frontal lobe function were observed when assessed using the Sustained Working Memory Test-Overall Mid-Day Index [2,44].
Another study showed improved cognitive function in OSAHS patients using the objective Montreal Cognitive Assessment tool. It was not specified which cognitive function was improved [50]. Although there was no improvement in subjective cognitive scores. Reassuringly, the respiratory and sleep parameters (total sleep time, sleep latency, wake after sleep onset, sleep stages, mean oxygen saturation, time spent <90>
Consistent with the APPLES study [44], Chong et al [51] also identified significantly improved somnolence levels in mild to moderate AD patients and OSAHS patients using PAP. These studies show that PAP improves sleep quality which may improve sleep fragmentation and cognitive impairment symptoms and possibly delay aMCI onset. This study also demonstrated that those with mild to moderate AD can tolerate PAP, and a diagnosis of AD should not deter trialling PAP treatment.
Interestingly, Dunietz et al [46] performed a retrospective study over a 2-year period using medical insurance database to identify the association between PAP usage and a diagnosis of MCI/AD in an elderly population of 53,321 people. They found that patients reported to be using PAP treatment was associated with lower odds of also possessing a diagnosis of MCI/AD. Hence PAP users were less likely to also have a diagnosis of MCI/AD. This supports a possible form of protection from using PAP treatment. However, there were potential biases in this report. In addition to the retrospective design, the data was collected through a medical insurance company. Therefore, limiting the data to a population which can afford health insurance and so excluding a key cohort such as low-income elderly individuals. Furthermore, the drive for financial reimbursement from recording effective PAP usage may also produce a bias, and consequently questions the reliability of obtaining accurate PAP usage information from medical insurance records.
This study is supported by Shieu et al [52], who performed a systematic review on the impact of PAP on developing MCI/AD. They found that 9 out of the 11 studies analysed demonstrated a protective mechanism from using PAP in the development of MCI/AD. This was suggested to result from several factors such as a delay in the development of MCI, a reduced rate of diagnosis of MCI/AD, slower decline in cognition or a slower rate of progression to AD. The progression of cognitive decline in the 2 studies that did not demonstrate PAP treatment as a protective mechanism was assessed using a variety of measures including the Trail Making Tests, and the Mini-Mental State Examination score. However, the Clinical Dementia Rating score showed a greater change in the non-adherent to PAP compared to PAP adherent participants. This highlights the impact of using different outcomes of subjective measures and the potential for misinterpretation of the efficacy of PAP treatment on cognition. In addition, half of the studies were classified as high risk or serious for bias in the results of 5 studies due to a lack of randomisation, limited control for confounders and failure to recruit to the target sample size.
A longitudinal study by Troussière et al [8] compared patients with mild to moderate AD and severe OSAHS with and without PAP treatment. They found that the progression of AD was mitigated with PAP intervention compared to those with no PAP treatment over a three-year period. This is supported in a randomised controlled trial by Cooke et al [20], an extension to the Ancoli-Israel et al [53] study. Although the sample size of this study was very small with just five patients per group, it supports the idea that PAP may be associated with improved cognitive function after 13 months of usage in patients with OSAHS and AD. Specifically, this study showed less cognitive decline in the PAP group (moderate to large effect sizes) compared to the non-PAP group, including executive functioning (effect size = 0.7); whereas the non-PAP group were reported to have deteriorated [20].
Ancoli-Israel et al [53] performed a randomised double-blind placebo-controlled trial in a similar cohort. They demonstrated no significant difference in cognitive function after a short trial period of just three weeks of PAP treatment compared to sham PAP. However, the effects of PAP treatment were almost immediate with improvements in sleep architecture demonstrated after just one night of use. Cooke et al [54] found significant alterations in sleep architecture towards normalisation, particularly in wake after sleep onset and slow wave sleep after just three weeks of treatment. This implies that improvements in cognitive impairment are not instantaneous and hence there is a need for a period to rectify the sleep architecture before cognitive changes are evident.
Furthermore, a study by Richards et al [21] using a quasi-experimental design and hence randomisation was not used, observed improvements in psychomotor/cognitive processing speed, memory, sleepiness, and daily functioning in MCI and OSAHS patients after PAP treatment for one year. This supports the hypothesis that PAP intervention may slow cognitive decline. Interestingly, the improvements were observed at different time periods with memory and daily function at 6 months, and attention and sleepiness at 1 year; highlighting the importance of appropriate time milestones during the longitudinal follow up.
There is a similarity in the decline of neuropsychological test outcomes in AD and OSAHS, affecting memory, attention, psychomotor, executive function, and verbal and visuospatial skills [1, 5]. The most affected function is attention in those with OSAHS and is a potential catalyst for impairment in other cognitive domains including memory and executive function [3,15]. Based on findings from these studies, the effect of PAP treatment in cognitive function is still under debate as contrasting evidence has been found. These reviews highlight the heterogeneity of studies, with mostly cross-sectional methodologies, single-centre trials, short treatment follow ups, predominantly male cohorts, diverse age and OSAHS severity ranges used. Therefore, these varying methodologies need to be addressed to obtain more reproducible results.
Although these studies reveal a consensus that PAP treatment can improve cognitive impairment through improving sleep quality and nocturnal oxygenation levels in aMCI/AD patients, there are several methodological flaws. Most studies included patients with moderate to severe OSAHS this is likely to demonstrate as much of an effect as possible, and therefore omitting mild OSAHS. This may, however, be a detriment to the outcome of the results with the more severe the OSAHS, the least reversal in cognitive function potentially occurs. Interestingly, Osorio et al [19] found the age of MCI onset to be younger in those with OSAHS, and PAP treatment delayed MCI onset comparable to those with no OSAHS. This suggests that PAP treatment may have a protective influence on cognition and hence possibly more effective in younger patients over a longer period. This emphasises the importance of treating OSAHS early including those with mild OSAHS, before OSAHS severity increases, and irreversible damage in the brain is experienced [5,15,66,67].
There was also a lack of quality assurance of PAP treatment, such as reviewing interface leak, comfort, and oxygen and sleep parameters when using PAP. Suboptimal treatment can not only impair the effectiveness, but also the tolerability of PAP and ultimately the adherence [68,69]. This may dilute the potential positive effects of the treatment on intermittent hypoxia and sleep fragmentation and ultimately the impact on cognition.
In support, a retrospective study by Costa et al [17] demonstrated the impact of suboptimal PAP adherence. They compared cognition with PAP adherence after 2-12 months of usage in MCI patients with OSAHS. Despite the non-adherent group (<4>
Conversely, a retrospective study by Skiba et al [7] found no difference in cognition between PAP adherent (≥6 hours/night) and non-adherent MCI patients. However, there were limitations that may explain the lack of significance including a 20-month discrepancy in the cognitive assessment between groups and the PAP cohort exhibiting higher intelligence levels. This yields to the cognitive reserve theory whereby those with a higher intelligence or IQ may provide ‘protection’ against cognitive decline [15,45]. This is thought to be due to possessing a larger cognitive reserve, or better compensation and hence using different areas of the brain to maintain normal function [70]. This may influence PAP effectiveness when measured using neuropsychological assessments which may not be sensitive enough to detect changes in those with higher intelligence [3].
Therefore, the lack of a standardised definition of PAP adherence is arguably the most discernible methodological discrepancy with a very wide range included. The arbitrary threshold of ≥4 hours, 70% of the nights is commonly used, but studies may also define their own criteria [17,53,56]. A complication to standardising the threshold may be that it is dependent on the outcome being measured such as memory or daytime sleepiness [56]. Overall, this limits the interpretation of findings about the effectiveness of PAP treatment on cognitive function.
For example, Troussière et al [8] deemed good adherence as >5 nights/week, whereas both Costa et al [17] and Ancoli-Israel et al [53] accepted low adherence with PAP being used just 35% and 32% of the time, respectively. The adherence was also self-reported in some studies introducing further bias [19,71]. This may dilute the effect of PAP treatment on cognitive domains and therefore hinder any conclusions that can be made on the effects of PAP intervention on cognitive impairment.
There have been two recent systematic reviews on PAP adherence [56,72]. Lajoie et al [56] determined the PAP adherence threshold and the effects of adherence level on cognition in patients with OSASHS and neurodegenerative diseases (MCI, AD, Parkinson’s disease, and multiple system atrophy). Using 8 studies, the MCI and AD group demonstrated a wide range of adherence (28-61%) and overall, those with aMCI/AD typically demonstrated lower adherence [56]. Oliver et al [72] found approximately half of the participants with OSAHS and MCI/AD reached the threshold of ≥4 hours, 70% of the nights in all 5 studies included. However, in 3 out of 5 studies, a wide adherence range was reported from 3.2 to 6.3 hours per night [72]. Despite this, it was found that PAP adherence in the OSAHS population with MCI/AD did not differ to the general elderly population.
An example of a study demonstrating acceptable adherence is Richards et al [55]. They found those with aMCI were able to tolerate PAP treatment with 73% of the cohort achieving adherence of ≥4 hours for 70% of the nights. Though this level of adherence may have been higher due to the behavioural support provided throughout the study including social support and motivational enhancements which helped to reinforce the participants health related goals. The number of behavioural support sessions attended and the severe severity of OSAHS was associated with increased adherence. Nonetheless, this study has shown that adherence in this cohort is possible.
Influencing factors of the level of adherence includes the time given to adapt to treatment. Across several studies the range varied from 3 weeks to 3.3 years. Another factor is motivation to continue the treatment. For example, it has been shown that unmarried patients were more likely to abandon PAP treatment [21,56]. Finally, at what point PAP treatment is introduced to a patient with aMCI/AD should also be considered. Although Skiba et al [7] found no difference in adherence in those with and without aMCI, the APPLES study [44] and Chong et al [51] both demonstrated that those with moderate AD can tolerate PAP treatment, therefore there may come a point in the AD pathway when PAP acceptance is more difficult.
Limitations of the review include the use of studies with small sample sizes, which included predominately male participants and a lack of ethnic diversity. There is an urgent need for studies where equal representation of different populations is included. This will demonstrate the full impact of PAP treatment in the general population.
Further limitations of the studies included in this review are the variability of methodologies including different adherence thresholds for PAP, and a lack of clarity in the optimisation of PAP such as leak level. Providing information on the PAP parameters will help determine PAP efficacy. There are also different follow up periods, and a mixture of qualitative and quantitative measurement tools used for cognition and sleep architecture. Finally, the different baseline severities of OSAHS and aMCI/AD selected is also present across studies. Such heterogeneity poses difficulty comparing study outcomes and the interpretation of PAP treatment on cognition.
PAP has been used for the treatment of OSAHS for several decades, and despite the compelling results of the association between OSAHS and AD, the evidence concerning PAP effectiveness in improving cognitive impairment has been varied. PAP treatment correlates well with attention and somnolent levels. PAP intervention has shown to improve sleep architecture, increase Aβ clearance and improve brain function and fluid diffusivity in OSAHS patients and in those with OSAHS and aMCI/AD.
Unfortunately, the results are often marred by methodological differences across the studies and hence the heterogeneity restricts the generalisability of the results. There is much discrepancy in the level of acceptable adherence of PAP use. In addition, the reliance on self-reported data of the adherence of PAP treatment as opposed to objective measures is less robust. The full effects of PAP treatment may also be dependent on age, OSAHS severity, when the treatment started, and aMCI/AD severity of the patient. Nonetheless, evidence implies that PAP treatment may slow aMCI/AD development and progression in patients with OSAHS.
Therefore, future research should focus on longitudinal studies to fully understand the complex relationship between OSAHS and AD neuropathology and specifically the effect of intermittent hypoxia and sleep fragmentation influence in neurodegeneration, the long-term efficacy of PAP to revert key features of AD such as the progression of cognitive decline. It is equally important to establish the optimal protocols of PAP adherence required to obtain maximum protective effect and identify the time threshold to start PAP treatment for slowing aMCI progression.
This paper was generated as part of the PhD research for the Higher Specialist Scientific Training (HSST) programme currently being undertaken by Sara Parsons. This programme is provided and funded by the National School of Healthcare Science. Prof Sonia Corrêa-Müller is the Programme Director for the academic component of the HSST – the Doctoral Clinical Science -Respiratory and Sleep Specialism delivered by Manchester Metropolitan University and Sara Parsons PhD supervisor.
We thank Mr Martyn Bucknall (Healthcare Science programme at St. George’s University) and Dr Jane Watson (Respiratory department at St George’s Hospital) for proof-reading the manuscript.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
